Old Web
English
Sign In
Acemap
>
authorDetail
>
Stephen Castenada
Stephen Castenada
Bristol-Myers Squibb
Pharmacology
Immunology
Imatinib
Medicine
Dasatinib
4
Papers
57
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts
2006
Journal of Clinical Oncology
Francis Y. Lee
Amy Camuso
Stephen Castenada
Christine Flefleh
I. Ingio
David Kan
Kelly McGlinchey
Krista Menard
William C. Rose
Show All
Source
Cite
Save
Citations (31)
Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.
2005
Blood
Francis Y. Lee
Mei-Li Wen
Amy Camuso
Stephen Castenada
Krista Fager
Christine Flefleh
Ivan Inigo
Roger Luo
David Kan
Veeraswamy Manne
Kelly McGlinchey
Richard Smykla
Roberto Weinmann
Robert Kramer
Show All
Source
Cite
Save
Citations (5)
Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).
2005
Blood
Francis Y. Lee
Mei-Li Wen
Rajeev S. Bhide
Amy Camuso
Stephen Castenada
Krista Fager
Christine Flefleh
Ivan Inigo
David Kan
Roger Luo
Kelly McGlinchey
Richard Smykla
Robert Wild
Robert M. Borzilleri
Louis J. Lombardo
Show All
Source
Cite
Save
Citations (19)
Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.
2004
Blood
Feng Roger Luo
Zheng Yang
Amy Camuso
Richard Smykla
Stephen Castenada
Christine Flefleh
Krista Fager
Ivan Inigo
David Kan
Kelly McGlinchey
Mei-Li Wen
Robert Wild
Robert M. Borzilleri
Louis J. Lombardo
Robert Kramer
Francis Y. Lee
Show All
Source
Cite
Save
Citations (2)
1